GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » PS Ratio

Urologix (Urologix) PS Ratio : 0.00 (As of Apr. 28, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Urologix PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Urologix's share price is $0.0001. Urologix's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2015 was $0.57. Hence, Urologix's PS Ratio for today is 0.00.

The historical rank and industry rank for Urologix's PS Ratio or its related term are showing as below:

ULGX's PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 3.19
* Ranked among companies with meaningful PS Ratio only.

Urologix's Revenue per Sharefor the three months ended in Mar. 2015 was $0.13. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2015 was $0.57.

Back to Basics: PS Ratio


Urologix PS Ratio Historical Data

The historical data trend for Urologix's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urologix PS Ratio Chart

Urologix Annual Data
Trend Jun05 Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.05 1.10 0.67 0.44 0.26

Urologix Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.26 0.17 0.12 0.14

Competitive Comparison of Urologix's PS Ratio

For the Medical Devices subindustry, Urologix's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urologix's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Urologix's PS Ratio distribution charts can be found below:

* The bar in red indicates where Urologix's PS Ratio falls into.



Urologix PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Urologix's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0001/0.565
=0.00

Urologix's Share Price of today is $0.0001.
Urologix's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.57.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Urologix  (OTCPK:ULGX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Urologix PS Ratio Related Terms

Thank you for viewing the detailed overview of Urologix's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Urologix (Urologix) Business Description

Traded in Other Exchanges
N/A
Address
14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
Executives
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler director 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet director, officer: CEO 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore director
Guy C Jackson director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon officer: Chief Technology Officer
Bobby Ivan Griffin director 1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo officer: VP, Product Dev. & Operations 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote director 649 SUMMIT AVENUE, ST PAUL MN 55105

Urologix (Urologix) Headlines

From GuruFocus

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 16,900 Shares

By GuruFocus Research GuruFocus Editor 12-09-2009

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-17-2010

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 3,100 Shares

By GuruFocus Research GuruFocus Editor 12-07-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 5,200 Shares

By GuruFocus Research GuruFocus Editor 02-01-2011

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-21-2009